Skip to content
Clinical Trials – home

Follicular lymphoma stage III Basic Information

1 / 2 trials open to patients5 countries

In short

Follicular lymphoma stage III is an advanced form of a slow-growing blood cancer affecting the lymphatic system, where cancer has spread to lymph nodes on both sides of the diaphragm. While this stage indicates widespread disease, many treatment options are available, and understanding the condition helps patients navigate their journey with greater confidence.

Key points

  • Stage III follicular lymphoma means cancer has spread to lymph nodes on both sides of the diaphragm, but this slow-growing cancer allows many people to live well for years with proper management.
  • Most people are diagnosed at stage III or IV because the disease often doesn't cause symptoms in early stages, making regular medical check-ups important if you notice unusual swellings.
  • You may not need immediate treatment if you have no symptoms—watchful waiting is a valid approach that doesn't compromise survival outcomes.
  • The disease is characterized by a unique "waxing and waning" pattern where lymph nodes may naturally shrink and enlarge over time without treatment.
  • While currently not curable in adults, newer treatments including immunotherapy are helping people live longer and better with follicular lymphoma.
  • The chromosomal change t(14;18) occurs in about 85 to 90 percent of cases, though the exact trigger for this genetic alteration remains unknown.
  • Bone marrow involvement occurs in more than half of patients, which can affect blood cell production and cause symptoms like fatigue or easy bruising.
  • Despite being widespread at diagnosis, many people with stage III follicular lymphoma continue to feel relatively well and maintain good quality of life, especially without B symptoms.

Understanding Follicular Lymphoma Stage III

Follicular lymphoma is a type of non-Hodgkin lymphoma, which is cancer that affects the lymphatic system. The lymphatic system is part of your body's immune system and includes lymph nodes, vessels, and organs that help fight infections. In follicular lymphoma, cancer develops from B cells, which are a type of white blood cell that normally makes antibodies to protect you from illness. When these cells become cancerous, they don't work properly and instead multiply and grow out of control.

The term "follicular" comes from how these abnormal cells grow. They typically cluster together in clumps called follicles inside lymph nodes. Stage III means the cancer has spread to lymph nodes on both sides of the diaphragm. The diaphragm is a band of muscle that separates your chest from your abdomen, acting like a dividing line in your body.

Follicular lymphoma is considered an indolent or slow-growing cancer. This means it typically progresses gradually over time rather than rapidly. Because it grows slowly and often doesn't cause symptoms in the early stages, most people have stage III or stage IV disease by the time they receive a diagnosis. This doesn't necessarily mean the outlook is poor—it simply reflects the nature of how this particular cancer behaves.

How Common Is This Condition

Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. In the United States, approximately 15,000 to 20,000 new cases are diagnosed each year. Among all people with non-Hodgkin lymphoma in the UK, around 20 in 100 people have follicular lymphoma, making it the most common type of slow-growing lymphoma.

This condition mainly affects adults over the age of 60, with the median age at diagnosis being approximately 59 to 60 years old. However, people can be diagnosed at different ages. There is a slight predominance in women, meaning women are diagnosed with follicular lymphoma slightly more often than men.

The incidence of follicular lymphoma varies by ethnicity and geographic location. The disease is most common among White individuals. In western countries, follicular lymphoma accounts for about 10 to 20 percent of all lymphomas, though rates differ across populations. The incidence has remained relatively stable over time.

What Causes Follicular Lymphoma

Researchers do not fully understand what causes follicular lymphoma to develop. However, they have discovered that changes in chromosomes occur in about 85 percent of cases. These changes transform normal B cells into cancer cells. The hallmark of follicular lymphoma is a specific chromosomal change called t(14;18) translocation, which leads to increased production of a protein called BCL2. This chromosomal change is expressed in approximately 90 percent of cases.

These genetic changes are not inherited from your parents. Instead, they happen at some point during your lifetime. The exact trigger that causes these chromosomal changes remains unknown. Unlike some cancers that have clear environmental or lifestyle causes, follicular lymphoma does not have identified specific causes that people can avoid.

Once the chromosomal changes occur, the affected B cells begin to multiply and grow abnormally. These cancer cells don't function the way normal B cells do. Normal B cells help fight infections by making antibodies, but cancer cells lose this ability. Instead, they continue to multiply and accumulate in lymph nodes and potentially other organs like bone marrow. Over time, as more and more abnormal cells build up, they may eventually cause symptoms, though this process typically takes a long time because of the slow-growing nature of the disease.

Who Is At Risk

Several factors increase the likelihood of developing follicular lymphoma, though having these risk factors doesn't mean you will definitely get the disease. Age is one of the most significant risk factors. People aged 65 and older are more likely to develop this condition. The disease mainly affects adults, with the median age at diagnosis being around 59 to 60 years old.

Race and ethnicity also play a role in risk. People who are White receive this diagnosis more often than people of other races. The incidence varies by ethnicity, with the highest rates among White individuals. This pattern is consistent across different geographic locations in western countries.

Having a weakened immune system can increase the risk of non-Hodgkin lymphoma, which includes follicular lymphoma. However, specific environmental or lifestyle risk factors for follicular lymphoma have not been clearly established. Unlike some other cancers, there are no well-documented behaviors or exposures that people can modify to prevent the disease.

Signs and Symptoms

Many people with follicular lymphoma don't have any symptoms at all, especially in the early stages. This is one reason why the disease is often diagnosed at an advanced stage. When symptoms do appear, they tend to develop gradually because of the slow-growing nature of the cancer.

The most common symptom is painless swelling in one or more areas of the body. This typically occurs in the neck, armpit, or groin where lymph nodes are located. These swellings are actually enlarged lymph nodes where the cancer cells have accumulated. The swellings are usually painless, which distinguishes them from swollen lymph nodes caused by infections, which often hurt.

Some people experience what doctors call B symptoms. These include heavy sweating at night (often soaking through bedclothes), high temperatures that come and go without obvious cause, and unexplained weight loss. Weight loss is considered significant if you lose more than one-tenth of your body weight over six months without trying to lose weight. These symptoms can affect how treatment decisions are made.

Other symptoms may include feeling very tired, even after rest. This is called fatigue and is different from normal tiredness because it doesn't improve with sleep. Follicular lymphoma can sometimes develop outside the lymph nodes, such as in bone marrow. When bone marrow is affected, it may cause low red blood cell counts leading to anemia, which makes people feel tired or breathless. It can also cause low platelet counts, leading to easy bruising or bleeding problems.

A characteristic feature of follicular lymphoma is that lymph nodes may wax and wane, meaning they can get larger and smaller over time, sometimes for years. This pattern is quite typical of this particular type of lymphoma.

Preventing Follicular Lymphoma

Unfortunately, there are no proven methods to prevent follicular lymphoma because the exact causes are not known. The chromosomal changes that lead to the disease happen spontaneously during a person's lifetime and are not inherited, so there is nothing specific people can do to avoid these changes.

Since specific environmental exposures or lifestyle factors that cause follicular lymphoma have not been identified, there are no particular behaviors to avoid or adopt for prevention. This differs from some other types of cancer where lifestyle modifications like not smoking or limiting alcohol can reduce risk.

However, maintaining overall good health through a balanced diet, regular exercise, and managing stress can support your immune system and general well-being. While these practices may not specifically prevent follicular lymphoma, they contribute to better overall health and can help your body better tolerate treatment if you are diagnosed.

If you notice any unusual symptoms, particularly painless swelling in your neck, armpit, or groin, or if you experience unexplained fever, night sweats, or significant weight loss, it's important to see your doctor promptly. Early detection allows for timely diagnosis and treatment planning.

How The Disease Affects Your Body

In follicular lymphoma, the normal function of the lymphatic system becomes disrupted. The lymphatic system is an important part of your immune system, containing organs and tissues that help protect your body from infection and disease. It includes lymph vessels (thin tubes that carry lymph fluid), lymph nodes (small bean-shaped structures that filter lymph), and organs like the spleen and bone marrow.

In a healthy person, B cells develop in the bone marrow and mature in lymphoid tissues. These cells normally produce antibodies that help fight infections. When follicular lymphoma develops, genetic changes cause B cells to become cancerous. The chromosomal translocation t(14;18) leads to overproduction of BCL2 protein, which prevents the abnormal cells from dying when they should. This allows cancer cells to accumulate.

The cancerous B cells typically cluster in follicle-like patterns within lymph nodes. In stage III disease, these abnormal cells have spread to lymph nodes on both sides of the diaphragm. This means lymph nodes both above and below the diaphragm contain cancer cells. The cancer cells may also spread to the bone marrow, which occurs in more than 50 percent of patients. When bone marrow is affected, it can interfere with normal blood cell production.

Because the cancer cells don't function properly, they cannot help fight infections like normal B cells would. However, because follicular lymphoma grows slowly, the immune system may continue to function reasonably well for some time. The accumulation of cancer cells in lymph nodes causes them to swell, which is often visible or palpable, particularly in the neck, armpits, or groin.

The slow growth pattern means that follicular lymphoma typically doesn't cause dramatic or sudden changes in the body. Instead, changes occur gradually over months or even years. Some people may notice their lymph nodes get bigger and smaller over time, a pattern characteristic of this disease. Despite being widespread at stage III, many people continue to feel relatively well, especially if they don't have B symptoms.

Did you know?

  1. The hallmark genetic change in follicular lymphoma, the t(14;18) chromosomal translocation, can actually be detected in the blood of some healthy people who never develop the disease, suggesting additional factors are needed for cancer to develop.
  2. Follicular lymphoma is characterized by a unique pattern where lymph nodes may spontaneously shrink and grow larger again over years, sometimes without any treatment, a behavior called "waxing and waning" that's rarely seen in other cancers.
  3. Most people with follicular lymphoma "die with it, not from it," meaning they live with the disease for many years and often pass away from other causes rather than the lymphoma itself, reflecting its typically slow progression.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Follicular lymphoma stage III

Recruiting trials first

See all 2 trials →
Quick filters

2 clinical trials in this condition

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.
See all 2 trials →filters applied: condition = Follicular lymphoma stage III

Related conditions in the same therapeutic area

Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).